江苏龙网

  1. 首页 > 生活 > >

肠菌博士|改变皮肤微生态：益生菌在皮肤病中的应用( 八 )


45 Fabbrocini G, Bertona M, Picazo O et al. Supplementation with Lactobacillus rhamnosus SP1 normalises skin expression of genes implicated in insulin signalling and improves adult acne. Benef Microbes 2016; 7:625–30.
46 Yu Y, Champer J, Garban H et al. Typing of Propionibacterium acnes: a review of methods and comparative analysis. Br J Dermatol 2015; 172:1204–9.
47 McDowell A, Nagy I, Magyari M et al. The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution. PLOS ONE 2013; 8: e70897.
48 Scholz CF, Jensen A, Lomholt HB et al. A novel high-resolution single locus sequence typing scheme for mixed populations of Propionibacterium acnes in vivo. PLOS ONE 2014; 9:e104199.
49 Fitz-Gibbon S, Tomida S, Chiu BH et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol 2013; 133:2152–60.
50 Tomida S, Nguyen L, Chiu BH et al. Pan-genome and comparative genome analyses of Propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. MBio 2013; 4:e00003–13.
51 Yu Y, Champer J, Agak GW et al. Different Propionibacterium acnes phylotypes induce distinct immune responses and express unique surface and secreted proteomes. J Invest Dermatol 2016; 136:2221–8.
52 Kober MM, Bowe WP. The effect of probiotics on immune regulation, acne, and photoaging. Int J Womens Dermatol 2015; 1:85–9.
53 Kang BS, Seo JG, Lee GS et al. Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J Microbiol 2009; 47:101–9.
54 AOBiome Therapeutics. AOBiome Therapeutics reports positive efficacy results from phase 2b clinical trial of ammonia oxidizing bacteria (AOB) for the treatment of acne vulgaris. Available at: https://www.aobiome.com/pressreleases/aobiome-therapeuticsreports-positive-efficacy-results-from-phase-2b-clinical-trial-of-ammonia-oxidizing-bacteria-aob-for-the-treatment-of-acne-vulgaris (last accessed 12 June 2019).
55 Nodake Y, Matsumoto S, Miura R et al. Pilot study on novel skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe – a blinded randomized clinical trial. J Dermatol Sci 2015; 79:119–26.
56 Wang Y, Kuo S, Shu M et al. Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: implications of probiotics in acne vulgaris. Appl Microbiol Biotechnol 2014; 98:411–24.
57 Liu J, Yan R, Zhong Q et al. The diversity and host interactions of Propionibacterium acnes bacteriophages on human skin. ISME J 2015; 9:2078–93.
58 Marinelli LJ, Fitz-Gibbon S, Hayes C et al. Propionibacterium acnes bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates. MBio 2012; 3:e00279–12.
59 Brown TL, Petrovski S, Dyson ZA et al. The formulation of bacteriophage in a semi solid preparation for control of Propionibacterium acnes growth. PLOS ONE 2016; 11:e0151184.


推荐阅读


上一篇：营养师李美糖|冬季荨麻疹来势汹汹，过敏体者需要关注三个方面可防止加重

下一篇：直肠癌|5个异常“暴露”直肠癌，你早该发现了，只是不重视！